Join a Clinical Trial
Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each clinical trial.
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
Complete Title: Phase II Study of Osimertinib (AZD9291) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR.
Trial Phase: II
Investigator: Christina Baik
This phase II trial studies how well osimertinib works in treating patients with non-small cell lung cancer with EGFR exon 20 insertion mutation that is stage IIIB-IV or has come back after a period of improvement (recurrent). Osimertinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Keywords:
- Lung Carcinoma, Non-Small-Cell (NSCLC)
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
Contact Us
If you are seeking to schedule an appointment, we are here to help. You can either call us or fill out our online appointment request form.